Researchers at Weill Cornell Medicine and MIT have uncovered a molecular trigger that transforms colorectal cancer cells into highly invasive predators capable of spreading to the liver. The culprit is not a genetic mutation, but rather the loss of a gene regulator called GATA6, which normally keeps intestinal cells locked into their specialized roles.
The discovery, published in Cell Stem Cell, points to a fundamentally different understanding of how colorectal cancer metastasizes. For decades, scientists hunted for specific DNA mutations that might drive liver spread. They found none. Instead, the Weill Cornell and MIT team identified an epigenetic switch, one that flips genes on and off without altering the underlying DNA code itself.
"We discovered that GATA6 loss acts as a critical switch that can change cancer cells in the primary tumor from non-metastatic to pro-metastatic," said Dr. Norihiro Goto, who co-led the work at Weill Cornell's Division of Gastroenterology and Hepatology. "Our findings suggest that epigenetic changes may be more important for promoting liver metastasis."
GATA6 normally functions as a molecular identity keeper, anchoring intestinal cells in their specialized state. When the research team examined tissue samples from patients with colorectal cancer that had spread to the liver, they found GATA6 levels were dramatically reduced. Even more troubling, low GATA6 expression correlated with poorer survival outcomes.
From Rigid to Radical
The transformation occurs through a process called lineage plasticity, essentially the ability of cancer cells to shed their fixed identity and become something more primitive and adaptive. When GATA6 vanishes, colorectal cancer cells activate fetal-like genetic programs that equip them for survival in hostile environments and travel through the bloodstream.
To observe this shift in real time, the researchers built a laboratory model using organoids derived from existing liver metastases. These miniature three-dimensional tumor clusters were implanted into mouse colons, where they grew increasingly aggressive and eventually spread to the liver. By repeating this process, scientists watched cancer cells gradually acquire metastatic capabilities.
One hallmark of this cellular hijacking is the loss of a marker called LGR5, typically found in intestinal stem cells. Prior research had shown that LGR5-negative cells are particularly adept at initiating liver metastases. The new study confirmed that GATA6 loss specifically triggers this transition, converting LGR5-positive cancer cells into the LGR5-negative variants primed for organ invasion.
Conversely, when the researchers restored GATA6 activity in these cells or activated related molecular pathways, metastatic potential plummeted. In mouse models, deleting GATA6 dramatically increased the frequency and burden of liver metastases while leaving primary tumor growth largely unchanged, suggesting that metastatic success hinges more on cellular transformation than on the sheer size or speed of the original cancer.
"When researchers analyze patient samples from liver metastases, we fail to capture the important signals occurring in the early stages of the metastatic process," Dr. Goto explained. The organoid approach allowed his team to witness those critical early transitions that traditional tissue analysis cannot reveal.
The findings open a path toward new clinical tools and treatments. GATA6 levels might serve as a biomarker, helping oncologists identify which patients face elevated metastatic risk and therefore warrant more intensive surveillance or aggressive intervention. The research also suggests a therapeutic strategy centered on preventing cancer cells from entering their hyper-plastic, metastasis-prone state.
However, blocking these cellular transitions without disrupting normal tissue repair presents a formidable challenge, since the body naturally employs similar biological programs during wound healing and stress adaptation. The next phase of research will focus on finding vulnerabilities unique to GATA6-deficient cancer cells that could be exploited by new drugs, while also examining how the tumor microenvironment influences these dangerous cellular shape-shifts.
Metastatic colorectal cancer remains the leading cause of death from the disease, yet treatments have remained largely unchanged. Any strategy that interrupts the spread process before it takes hold could shift the outcome dramatically.
Author Jessica Williams: "This research reframes how we think about cancer's most lethal trick, moving the spotlight from raw mutations to the cellular plasticity that makes invasion possible."
Comments